These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

266 related items for PubMed ID: 18388031

  • 21. Treatment of long-distance intermittent claudication with pentoxifylline: a 12-month, randomized trial.
    De Sanctis MT, Cesarone MR, Belcaro G, Nicolaides AN, Griffin M, Incandela L, Bucci M, Geroulakos G, Ramaswami G, Vasdekis S, Agus G, Bavera P, Ippolito E.
    Angiology; 2002; 53 Suppl 1():S13-7. PubMed ID: 11865829
    [Abstract] [Full Text] [Related]

  • 22. Systematic review of the efficacy of cilostazol, naftidrofuryl oxalate and pentoxifylline for the treatment of intermittent claudication.
    Stevens JW, Simpson E, Harnan S, Squires H, Meng Y, Thomas S, Michaels J, Stansby G.
    Br J Surg; 2012 Dec; 99(12):1630-8. PubMed ID: 23034699
    [Abstract] [Full Text] [Related]

  • 23. Cost-effectiveness of cilostazol, naftidrofuryl oxalate, and pentoxifylline for the treatment of intermittent claudication in people with peripheral arterial disease.
    Meng Y, Squires H, Stevens JW, Simpson E, Harnan S, Thomas S, Michaels J, Stansby G, O'Donnell ME.
    Angiology; 2014 Mar; 65(3):190-7. PubMed ID: 23378195
    [Abstract] [Full Text] [Related]

  • 24. Measuring treatment effects of cilostazol on clinical trial endpoints in patients with intermittent claudication.
    Smith JA.
    Clin Cardiol; 2002 Mar; 25(3):91-4. PubMed ID: 11892686
    [Abstract] [Full Text] [Related]

  • 25. Treatment of severe intermittent claudication with pentoxifylline: a 40-week, controlled, randomized trial.
    Cesarone MR, Belcaro G, Nicolaides AN, Griffin M, De Sanctis MT, Incandela L, Geroulakos G, Ramaswami G, Cazaubon M, Barsotti A, Vasdekis S, Bavera P, Ippolito E.
    Angiology; 2002 Mar; 53 Suppl 1():S1-5. PubMed ID: 11865828
    [Abstract] [Full Text] [Related]

  • 26. New treatment options in intermittent claudication: the US experience.
    Hiatt WR.
    Int J Clin Pract Suppl; 2001 Apr; (119):20-7. PubMed ID: 11355276
    [Abstract] [Full Text] [Related]

  • 27. Treatment of intermittent claudication: cilostazol.
    Collins P, Brittenden J.
    Hosp Med; 2004 Aug; 65(8):466-70. PubMed ID: 15330347
    [Abstract] [Full Text] [Related]

  • 28. Treatment of intermittent claudication with pentoxifylline and cilostazol.
    Tjon JA, Riemann LE.
    Am J Health Syst Pharm; 2001 Mar 15; 58(6):485-93; quiz 494-6. PubMed ID: 11286146
    [Abstract] [Full Text] [Related]

  • 29. L-Carnitine plus cilostazol versus cilostazol alone for the treatment of claudication in patients with peripheral artery disease: a multicenter, randomized, double-blind, placebo-controlled trial.
    Goldenberg NA, Krantz MJ, Hiatt WR.
    Vasc Med; 2012 Jun 15; 17(3):145-54. PubMed ID: 22615190
    [Abstract] [Full Text] [Related]

  • 30. Cilostazol: improving walking distance in patients with intermittent claudication.
    Collinson DJ, Donnelly R.
    Expert Rev Cardiovasc Ther; 2004 Jul 15; 2(4):503-9. PubMed ID: 15225110
    [Abstract] [Full Text] [Related]

  • 31. Effect of cilostazol on walking distances in patients with intermittent claudication caused by peripheral vascular disease.
    Money SR, Herd JA, Isaacsohn JL, Davidson M, Cutler B, Heckman J, Forbes WP.
    J Vasc Surg; 1998 Feb 15; 27(2):267-74; discussion 274-5. PubMed ID: 9510281
    [Abstract] [Full Text] [Related]

  • 32. Acenocoumarol and pentoxifylline in intermittent claudication. A controlled clinical study. The APIC Study Group.
    Dettori AG, Pini M, Moratti A, Paolicelli M, Basevi P, Quintavalla R, Manotti C, Di Lecce C.
    Angiology; 1989 Apr 15; 40(4 Pt 1):237-48. PubMed ID: 2650578
    [Abstract] [Full Text] [Related]

  • 33. The effect of pain-free treadmill training on fibrinogen, haematocrit, and lipid profile in patients with claudication.
    Mika P, Wilk B, Mika A, Marchewka A, Nizankowski R.
    Eur J Cardiovasc Prev Rehabil; 2011 Oct 15; 18(5):754-60. PubMed ID: 21450630
    [Abstract] [Full Text] [Related]

  • 34. Medical management of peripheral arterial disease.
    Creager MA.
    Cardiol Rev; 2001 Oct 15; 9(4):238-45. PubMed ID: 11405904
    [Abstract] [Full Text] [Related]

  • 35. Comparative evaluation of pentoxifylline, buflomedil, and nifedipine in the treatment of intermittent claudication of the lower limbs.
    Chacón-Quevedo A, Eguaras MG, Calleja F, Garcia MA, Roman M, Casares J, Muñoz I, Concha M.
    Angiology; 1994 Jul 15; 45(7):647-53. PubMed ID: 8024164
    [Abstract] [Full Text] [Related]

  • 36. Pentoxifylline in the nonoperative management of intermittent claudication.
    Kokesh J, Kazmers A, Zierler RE.
    Ann Vasc Surg; 1991 Jan 15; 5(1):66-70. PubMed ID: 1997079
    [Abstract] [Full Text] [Related]

  • 37. Effect of the novel antiplatelet agent cilostazol on plasma lipoproteins in patients with intermittent claudication.
    Elam MB, Heckman J, Crouse JR, Hunninghake DB, Herd JA, Davidson M, Gordon IL, Bortey EB, Forbes WP.
    Arterioscler Thromb Vasc Biol; 1998 Dec 15; 18(12):1942-7. PubMed ID: 9848888
    [Abstract] [Full Text] [Related]

  • 38. Pentoxifylline for intermittent claudication.
    Salhiyyah K, Senanayake E, Abdel-Hadi M, Booth A, Michaels JA.
    Cochrane Database Syst Rev; 2012 Jan 18; 1():CD005262. PubMed ID: 22258961
    [Abstract] [Full Text] [Related]

  • 39. Interleukin-10 serum levels and systemic endothelial vasoreactivity in patients with coronary artery disease.
    Fichtlscherer S, Breuer S, Heeschen C, Dimmeler S, Zeiher AM.
    J Am Coll Cardiol; 2004 Jul 07; 44(1):44-9. PubMed ID: 15234404
    [Abstract] [Full Text] [Related]

  • 40. [Cilostazol is effective and safe option for the treatment of intermittent claudication. Results of the NOCLAUD study].
    Farkas K, Járai Z, Kolossváry E.
    Orv Hetil; 2017 Jan 07; 158(4):123-128. PubMed ID: 28116935
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 14.